Abstract
The aim of this study was to characterize the LAK cell subpopulation on which Prothymosin-alpha (ProT alpha) exerts its enhancing effect on cytotoxicity. We investigated the role of ProT alpha on LAK induction from peripheral blood lymphocytes (PBL) and NK-enriched cells, both cultured for 5 weeks with IL-2 and ProT alpha. The different cultures were separated into several subsets throughout the culture time using two color fluorescence activated cell sorting (FACS) and CD56, CD16, CD2 and CD8 monoclonal antibodies. Each cell subset was then tested for cytotoxicity against K562 and Daudi cells. The CD16+ CD2- subset from both, PBL and NK-enriched cells, was the only subset on which ProT alpha had an effect, significantly enhancing this subpopulation. Within the CD16 population, the cells CD16+ CD2+ were the most cytotoxic, although CD16+ CD2- cells were also cytotoxic. ProT alpha only potentiated the cytotoxicity of CD16+ CD2- subset significantly, with 29% and 41% for K562 and Daudi cells, respectively.
References
Aug 15, 1975·International Journal of Cancer. Journal International Du Cancer·R B HerbermanD H Lavrin
Feb 1, 1979·International Journal of Cancer. Journal International Du Cancer·L C AnderssonC G Gahmberg
Apr 1, 1991·European Journal of Immunology·E VivierP Anderson
Jan 1, 1991·International Journal of Immunopharmacology·O J CorderoM Nogueira
Jan 1, 1991·Cancer Investigation·E Lotzová
Jun 1, 1990·Cellular Immunology·G C ManaraG De Panfilis
May 1, 1990·The Journal of Experimental Medicine·A NaglerJ H Phillips
Jan 1, 1990·International Journal of Immunopharmacology·K D LeichtlingM B Sztein
Dec 14, 1989·Nature·L L LanierJ H Phillips
Jan 1, 1989·International Journal of Immunopharmacology·C FavalliE Garaci
Aug 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·M B SzteinA L Goldstein
Apr 9, 1987·The New England Journal of Medicine·S A RosenbergJ T Rubin
Dec 5, 1985·The New England Journal of Medicine·S A RosenbergJ T Vetto
Mar 1, 1981·The Journal of Experimental Medicine·T TimonenR B Herberman
Jan 1, 1981·Journal of Clinical Immunology·H F ProssM S Patterson
Mar 14, 1994·FEBS Letters·O J CorderoM Nogueira
Citations
Feb 3, 2006·Cancer Immunology, Immunotherapy : CII·Margarita SkopelitiOurania E Tsitsilonis
Mar 1, 2012·Cancer Immunology, Immunotherapy : CII·Kyriaki IoannouOurania E Tsitsilonis
Jan 1, 1996·Life Sciences·O J CorderoM Nogueira
Nov 10, 2000·Peptides·A PiñeiroM Nogueira
Sep 24, 2013·BMC Immunology·Kyriaki IoannouOurania E Tsitsilonis
Apr 29, 2006·BMC Immunology·Preben BoysenAnne K Storset
May 4, 2013·Immunotherapy·Constantin N BaxevanisOurania E Tsitsilonis
Dec 1, 2001·Biological Chemistry·A PiñeiroM Nogueira
Nov 4, 2008·Molecular Immunology·Margarita SkopelitiOurania E Tsitsilonis
Jul 9, 2013·Journal of Immunological Methods·Pinelopi SamaraOurania Tsitsilonis
Dec 5, 2013·Arthritis Research & Therapy·Jacky WooGary C Starling
Aug 13, 2005·Molecular Membrane Biology·Francisco J SalgadoMontserrat Nogueira
Nov 14, 2019·Cancers·Anastasios I BirmpilisOurania Tsitsilonis